Multi-Analyte Liquid Biopsy for PDAC Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for detecting pancreatic ductal adenocarcinoma (PDAC) are inadequate, particularly for early-stage detection, as existing biomarkers lack sensitivity and specificity, and standard imaging techniques fail to detect occult metastases, leading to challenges in determining surgical resectability and staging.
Innovation Solution
A method involving the measurement of a set of circulating biomarkers including extra-cellular vesicle (EV) miRNA, EV mRNA, circulating cell-free DNA, and protein biomarkers, combined with machine learning algorithms, to diagnose, stage, and assess the efficacy of treatments for PDAC, using a magnetic separation filter device to isolate and analyze these biomarkers.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If standard imaging techniques (CT, MRI) are used for diagnosis and staging, then the methods are non-invasive and widely available, but they fail to detect occult metastases and lack sensitivity for early-stage disease
Solution Approach 1:
The patent combines multiple liquid biopsy biomarkers (circulating tumor DNA, EV miRNA, EV mRNA, and protein biomarkers) into a multi-analyte panel that is integrated with imaging techniques. This combination allows the detection of occult metastases through molecular markers in the blood, complementing the anatomical information from CT and MRI, thereby improving overall detection accuracy without replacing the established imaging methods.
Solution Approach 2:
The patent introduces liquid biopsy biomarkers as an intermediary tool that bridges the gap between standard imaging and direct tissue analysis. These biomarkers serve as mediators that can detect molecular evidence of disease and metastases that imaging cannot visualize, providing additional diagnostic information while maintaining the non-invasive nature of the overall approach.
2Reliability
If single biomarker assays are used for early detection, then the assays are simple and cost-effective, but they show low sensitivity for early-stage disease
Solution Approach 1:
The patent merges multiple biomarker assays into a single integrated multi-analyte panel that simultaneously measures circulating tumor DNA, EV miRNA, EV mRNA, and protein biomarkers. This combination increases sensitivity for early-stage detection by capturing multiple molecular signals from the tumor, while the panel is designed to be processed through a unified workflow that manages the complexity of analyzing multiple analytes together.
Solution Approach 2:
The patent develops a universal multi-analyte panel platform that can detect multiple types of biomarkers (DNA, RNA, proteins) from a single blood sample using a standardized protocol. This multi-functional approach allows the same system to assess various aspects of tumor biology simultaneously, improving early detection sensitivity without requiring separate complex procedures for each biomarker type.
3Reliability
If multi-analyte liquid biopsy panels are implemented, then sensitivity and specificity for early detection improve, but the cost and technical complexity of the assay increase
Solution Approach 1:
The patent segments the multi-analyte panel into distinct measurement modules for different biomarker types (DNA analysis, EV isolation and RNA analysis, protein detection), each optimized for its specific analyte. This segmentation allows each module to be developed and validated independently, simplifying the overall implementation while maintaining high diagnostic accuracy through the integration of results from all modules.
Solution Approach 2:
The patent optimizes various assay parameters including biomarker selection, detection thresholds, and processing conditions to balance diagnostic accuracy with implementation feasibility. By carefully tuning these parameters and selecting biomarkers with appropriate abundance and stability characteristics, the panel achieves high sensitivity and specificity while maintaining reasonable complexity for clinical implementation.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This approach achieves high accuracy (>90%) in identifying PDAC and distinguishing between metastatic and non-metastatic stages, improving early detection and surgical decision-making by providing a non-invasive, sensitive, and specific diagnostic tool.
Implementation Method 1
isolating a biological sample from the subject, using a magnetic separation filter device
Data Source
AI summary
Disclosed herein are methods for evaluating a disease or a condition in a subject. More particularly, disclosed herein are methods for determining or diagnosing a disease, methods for classifying a stage of a disease, methods for treating a disease or methods for assessing the efficacy of a therapy for treating a disease based on the measurement and the computational analysis of various disease-specific biomarkers.